Key terms
About PROF
Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PROF news
Apr 22
5:28pm ET
Profound Medical Unveils Q1 2024 Financials
Apr 22
4:37pm ET
Profound Medical Announces Q1 2024 Results Release
Apr 09
8:27am ET
Profound Medical to Present at Healthcare Investor Conference
Apr 09
8:07am ET
Profound Medical to Update at Healthcare Conference
Mar 11
10:22am ET
Profound Medical price target lowered to $10.80 from $12.75 at Alliance Global Partners
Mar 07
4:37pm ET
Profound Medical Reports Revenue Growth and Expansions
Mar 04
5:07pm ET
Profound Medical Showcases Innovations at Healthcare Conference
Feb 27
8:07am ET
Profound Medical’s Innovative Collaboration for Prostate Therapy
Feb 27
7:48am ET
Profound Medical, Siemens Healthineers collaborate for TULSA procedure access
No recent press releases are available for PROF
PROF Financials
Key terms
Ad Feedback
PROF Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PROF Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
